Eli Lilly's Triple-Target Weight Loss Drug Retatrutide Posts Striking Phase 3 Results

Eli Lilly's experimental drug retatrutide has cleared a major clinical milestone, delivering an average of 36.6 pounds of weight loss over 40 weeks in a phase 3 trial among people with type 2 diabetes — results that experts say surpass what has been seen with existing approved medications.

Retatrutide belongs to a next-generation class called GLP-3 agonists, which hit three hormone receptors simultaneously: GLP-1 (the same target as Ozempic's semaglutide), GIP (also targeted by Eli Lilly's tirzepatide), and the glucagon receptor. That triple mechanism makes it the first drug of its kind to reach large-scale clinical testing, and it was genuinely uncertain whether hitting all three targets would add meaningful benefit over the two-receptor approach.

The trial ran 40 weeks, and participants on the highest dose — 12 milligrams — lost an average of 36.6 pounds. Blood sugar control was also strong, with A1C levels dropping 1.7 to 2 percentage points across the dose groups. Rozalina McCoy, an endocrinologist at the University of Maryland, described the results as showing greater efficacy over placebo than previous trials of both tirzepatide and semaglutide — a notable benchmark given those drugs already transformed the obesity treatment landscape.

Side effects tracked closely with the established GLP-1 drug class: nausea, diarrhea, and vomiting were most common. One notable outlier was dysesthesia — a painful or burning skin sensation — reported in 2.3 to 4.5 percent of participants, which experts flagged for further investigation. Daniel Drucker of the University of Toronto, a leading figure in GLP-1 research who has previously consulted for Eli Lilly, called the safety and dropout profile reassuring and consistent with the broader drug class.

The data remain preliminary and have not yet been peer-reviewed or published in full. Experts also cautioned that the pace of weight loss — nearly 37 pounds in under a year — and the sharp A1C drop warrant careful monitoring for downstream effects. The broader conversation is already shifting toward access: McCoy emphasized that the most pressing challenge ahead is ensuring patients can reach and use these medications safely and equitably.